August 7

Bill Carpou, CEO, Octane

Mike Giaquinto, Senior Managing Director, SVB Leerink

A discussion about innovation in ophthalmology and the industry more broadly and where Rick sees the future of AbbVie.

Richard Gonzalez, Chairman of the Board and Chief Executive Officer, AbbVie

Jim Mazzo, Executive Chairman, Neurotech Advisor, Bain Capital

Elizabeth Yeu, MD, Partner, Virginia Eye Consultants (Moderator)

Jag Dosanjh, Senior Vice President, Eye Care at Allergan

Warren Foust, Worldwide President, Surgical Vision, Johnson & Johnson Vision

Caren Mason, President & CEO STAAR Surgical

Jim Mazzo, Executive Chairman, Neurotech Advisor, Bain Capital

Tom Mitro, President & COO, Aerie Pharmaceuticals

Michael Onuscheck, President, Global Business & Innovation, Alcon

What impact has COVID-19 had on future innovation? What technologies have been impacted or pivoted? What new technologies are being created as a result? What impact has COVID-19 had on clinical trials? How will industry interface with doctors in the future? Is the FDA changing regulations? What are the legal implications of COVID-19 in our industry?

John Hovanesian, MD, FACS, Private Practice, Harvard Eye Associates, Laguna Hills, CA Clinical Faculty, UCLA Jules Stein Eye Institute, Los Angeles, CA (Moderator)

Vance Thompson, MD, Vance Thompson Vision

Allison Shuren, Partner, Arnold & Porter

What is the future of premium practice? Has there been a financial impact in premium products? How do we provide a premium patient experience now? What is the future of innovation in telemedicine in a premium practice? What products will survive/which products will thrive?

John Hovanesian, MD, FACS, Private Practice, Harvard Eye Associates, Laguna Hills, CA Clinical Faculty, UCLA Jules Stein Eye Institute, Los Angeles, CA (Moderator)

Jeffry Weinhuff, Managing Partner, Visionary Ventures (Moderator)

Ehsan Sadri, MD, FACS, Visionary Eye Institute (Moderator)

Bobby Azamian, CEO, Tarsus

Robert Dempsey, CEO, TearClear

Elad Kedar, CEO, Orasiss

Kamran Hosseini, CEO, Surface

Matt Larson, President, Equinox

Monty Montoya, CEO, CorenaGen

Topic Include: Machine and deep learning and the application in medical image interpretation. Other AI tools that are available for ophthalmology. The future of AI in medicine and surgery.

Anthony Chang, MD, MBA, MPH, MS, Chief Intelligence and Innovation Officer, CHOC Children's Hospital

Bill Carpou, CEO, Octane